Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers

被引:87
|
作者
Temraz, Sally [1 ]
Mukherji, Deborah [1 ]
Shamseddine, Ali [1 ]
机构
[1] Amer Univ Beirut, Med Ctr, Div Hematol Oncol, Dept Internal Med, Beirut 110 72020, Lebanon
来源
关键词
colorectal cancer; drug resistance; phosphatidylinositol; 3-kinase; mitogen-activated protein kinase; MEK; TUMOR-GROWTH; AZD6244; ARRY-142886; PHASE-I; SELUMETINIB AZD6244; KINASE INHIBITORS; PIK3CA MUTATION; K-RAS; COMBINATION; RESISTANCE; PHOSPHORYLATION;
D O I
10.3390/ijms160922976
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Colorectal cancer (CRC) is a heterogeneous disease with multiple underlying causative genetic mutations. Genetic mutations in the phosphatidylinositol-3 kinase (PI3K) and the mitogen activated protein kinase (MAPK) pathways are frequently implicated in CRC. Targeting the downstream substrate MEK in these mutated tumors stands out as a potential target in CRC. Several selective inhibitors of MEK have entered clinical trial evaluation; however, clinical activity with single MEK inhibitors has been rarely observed and acquired resistance seems to be inevitable. Amplification of the driving oncogene KRAS(13D), which increases signaling through the ERK1/2 pathway, upregulation of the noncanonical wingless/calcium signaling pathway (Wnt), and coexisting PIK3CA mutations have all been implicated with resistance against MEK inhibitor therapy in KRAS mutated CRC. The Wnt pathway and amplification of the oncogene have also been associated with resistance to MEK inhibitors in CRCs harboring BRAF mutations. Thus, dual targeted inhibition of MEK and PI3K pathway effectors (mTOR, PI3K, AKT, IGF-1R or PI3K/mTOR inhibitors) presents a potential strategy to overcome resistance to MEK inhibitor therapy. Many clinical trials are underway to evaluate multiple combinations of these pathway inhibitors in solid tumors.
引用
收藏
页码:22976 / 22988
页数:13
相关论文
共 50 条
  • [1] PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers
    Wee, Susan
    Jagani, Zainab
    Xiang, Kay Xiaoqin
    Loo, Alice
    Dorsch, Marion
    Yao, Yung-Mae
    Sellers, William R.
    Lengauer, Christoph
    Stegmeier, Frank
    CANCER RESEARCH, 2009, 69 (10) : 4286 - 4293
  • [2] Combined inhibition of BRAF/ MEK and mTOR/Akt/PI3K pathways in BRAF-V600 mutated lung adenocarcinoma
    Hegedues, L.
    Idrizi, A.
    Okumus, O.
    Aigner, C.
    Hegedues, B.
    PNEUMOLOGIE, 2023, 77 : S92 - S93
  • [3] Horizontal Combination of MEK and PI3K/mTOR Inhibition in BRAF Mutant Tumor Cells with or without Concomitant PI3K Pathway Mutations
    Rittler, Dominika
    Molnar, Eszter
    Baranyi, Marcell
    Garay, Tamas
    Hegedus, Luca
    Aigner, Clemens
    Tovari, Jozsef
    Timar, Jozsef
    Hegedus, Balazs
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (20) : 1 - 18
  • [4] Receptor tyrosine kinases, not KRAS, activate PI3K in KRAS mutant colorectal cancers
    Ebi, Hiromichi
    Corcoran, Ryan B.
    Singh, Anurag
    Chen, Zhao
    Song, Youngchul
    Lifshits, Eugene
    Ryan, David P.
    Meyerhardt, Jeffrey A.
    Benes, Cyril
    Settleman, Jeffrey
    Cantley, Lewis C.
    Wong, Kwok-Kin
    Engelman, Jeffrey A.
    CANCER RESEARCH, 2011, 71
  • [5] Relationship of incomplete inhibition of PI3K pathway signaling and efficacy of cetuximab in KRAS wild-type colorectal cancers.
    Corcoran, Ryan Bruce
    Ebi, Hiromichi
    Ryan, David P.
    Meyerhardt, Jeffrey A.
    Engelman, Jeffrey A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [6] Mechanism-based combinatorial treatment of KRAS mutant colorectal cancer with MEK and PI3K pathway inhibitors
    Clarke, Paul A.
    Roe, Toby
    Workman, Paul
    CANCER RESEARCH, 2014, 74 (19)
  • [7] MEK and PI3K Dual-inhibition Elicits Pathway-specific and Mitochondrial Ubiquitination
    Bustos, Daisy
    Baughman, Joshua
    Phu, Lilian
    Dogan, Taner
    Forrest, William F.
    Hoeflich, Klaus P.
    Kirkpatrick, Donald S.
    MOLECULAR & CELLULAR PROTEOMICS, 2014, 13 (08) : S20 - S20
  • [8] Calmodulin and PI3K Signaling in KRAS Cancers
    Nussinov, Ruth
    Wang, Guanqiao
    Tsai, Chung-Jung
    Jang, Hyunbum
    Lu, Shaoyong
    Banerjee, Avik
    Zhang, Jian
    Gaponenko, Vadim
    TRENDS IN CANCER, 2017, 3 (03): : 214 - 224
  • [9] Alternative dosing of dual PI3K and MEK inhibition in cancer therapy
    Jokinen, Elina
    Laurila, Niina
    Koivunen, Jussi P.
    BMC CANCER, 2012, 12
  • [10] Dual inhibition of MEK/MAPK and PI3K/Akt in multiple myeloma
    Steinbrunn, T.
    Stuehmer, T.
    Sayehli, C.
    Chatterjee, M.
    Einsele, H.
    Bargou, R. C.
    ONKOLOGIE, 2012, 35 : 140 - 140